GlaxoSmithKline Pharmaceuticals Limited

NSEI:GLAXO Stock Report

Market Cap: ₹361.3b

GlaxoSmithKline Pharmaceuticals Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Bhushan Akshikar

Chief executive officer

₹33.9m

Total compensation

CEO salary percentage11.6%
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure2yrs
Board average tenure6yrs

Recent management updates

Recent updates

GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Apr 14
GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear

Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Feb 15
Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models

Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

Jan 18
Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?

GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Dec 28
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected

Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Oct 05
Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

Sep 12
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Mar 17
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet

Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

Sep 02
Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

Mar 02
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly

The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Mar 20
The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On

Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Feb 27
Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?

Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

Feb 06
Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?

What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

Jan 11
What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Dec 06
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain

Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Nov 01
Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts

Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

Oct 29
Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield

What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

Sep 29
What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?

If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Aug 30
If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today

Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

Aug 02
Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?

It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Jul 12
It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend

Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

Jul 07
Is GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) At Risk Of Cutting Its Dividend?

CEO Compensation Analysis

How has Bhushan Akshikar's remuneration changed compared to GlaxoSmithKline Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

₹5b

Sep 30 2023n/an/a

₹6b

Jun 30 2023n/an/a

₹6b

Mar 31 2023₹34m₹4m

₹6b

Compensation vs Market: Bhushan's total compensation ($USD407.29K) is about average for companies of similar size in the Indian market ($USD552.42K).

Compensation vs Earnings: Insufficient data to compare Bhushan's compensation with company performance.

CEO

Bhushan Akshikar

1.3yrs

Tenure

₹33,949,000

Compensation

Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...

Leadership Team

NamePositionTenureCompensationOwnership
Bhushan Akshikar
MD & Executive Director1.3yrs₹33.95mno data
Juby Chandy
Whole-Time Director & CFO2yrs₹54.13mno data
Ajay Nadkarni
VP of Administration & Real Estate and Company Secretaryno data₹11.57mno data
Amit Pandey
Executive Vice President of Legal2.2yrsno datano data
Simrat Sohal
Vice President of Ethics & Compliance1.2yrsno datano data
Ransom D'Souza
Executive Vice President of Communications & Government Affairs7yrsno datano data
Chinmay Sharma
Executive Vice President of Human Resources3.3yrsno datano data
Sukanya Choudhary
Executive Vice-President of Regulatory Affairsno datano datano data
Sougato Mitra
Head of Specialtyno datano datano data
Rashmi Hegde
Executive Vice President of Medical2.6yrsno datano data
Shourov Mukherjee
Executive Vice-President of Adult Vaccines1.8yrsno datano data
Upendra Singh
Executive Vice President of General Medicines1.3yrsno datano data

2.0yrs

Average Tenure

Experienced Management: GLAXO's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bhushan Akshikar
MD & Executive Directorno data₹33.95mno data
Juby Chandy
Whole-Time Director & CFO2yrs₹54.13mno data
Renu Karnad
Non-Executive Chairperson5yrs₹3.55m0.00035%
₹ 1.3m
Manu Anand
Independent Director1.9yrs₹2.30mno data
Damodarannair Sundaram
Non-Executive Independent Director14.8yrs₹2.90mno data
Subesh Williams
Non Executive Director7yrsno datano data
Pradeep Bhide
Non-Executive Independent Director13.5yrs₹2.85mno data
Anami Narayan Roy
Non-Executive Independent Director12.4yrs₹2.50mno data
Sunita Maheshwari
Non-Executive & Independent Director3.9yrs₹2.40mno data

6.0yrs

Average Tenure

67.5yo

Average Age

Experienced Board: GLAXO's board of directors are considered experienced (6 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.